Listed by the USPTO as CREWS, JARET JAMES
Tech Center 1600 • Art Units: 1623 1691 1693
This examiner grants 44% of resolved cases
CREWS, JARET JAMES works in USPTO Technology Center 1600 and art unit 1623. His record includes 98 resolved cases, a 43.9% allowance rate, and a 71.3% interview lift. The median time to allowance is 1228 days. The lower allowance outcome contrasts with a strong positive interview association, making examiner interviews a particularly important consideration for prosecution planning.
The leading companies are Sapreme Technologies B V, Research & Business Foundation Sungkyunkwan University, and Samsung Life Public Welfare Foundation. The leading firms are MAIER & MAIER, PLLC, Casimir Jones, S.C., and Ipsilon USA - NLO. These recurring participants provide context for the examiner’s biotechnology-related docket.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18077894 | METHOD OF PREDICTING THERAPEUTIC RESPONSE AND PROGNOSIS OF METASTATIC BREAST CANCER TO CHEMOTHERAPEUTIC AGENTS, AND TREATING METASTATIC BREAST CANCER | Non-Final OA | Samsung Life Public Welfare Foundation |
| 18032149 | COMPOSITIONS AND METHODS FOR DRUG DELIVERY | Non-Final OA | North Carolina State University |
| 17431462 | Methods for purifying bacterial polysaccharides | Final Rejection | Pfizer Inc. |
| 18709180 | Freshwater Biodegradable Mixed Ester Cellulose Esters | Non-Final OA | Eastman Chemical Company |
| 18256057 | FIBRE MIXTURE FOR YOUNG CHILDREN | Non-Final OA | N.V. Nutricia |
| 17422638 | COMPOSITIONS AND METHODS FOR INDUCING OR SUPPLEMENTING SOCS3 TO ABROGATE TUMOR GROWTH AND PROLIFERATIVE RETINOPATHY | Final Rejection | Children's Medical Center Corporation |
| 18510007 | COMPOSITIONS AND METHODS FOR HIGH STRINGENCY ISOLATION OF NUCLEIC ACIDS | Final Rejection | Duke University |
| 17597878 | ANTICANCER AGENTS | Final Rejection | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. |
| 18259146 | NOVEL GALACTOSIDE INHIBITOR OF GALECTINS | Final Rejection | GALECTO BIOTECH AB |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy43.9% of resolved applications examined by Jaret James Crews were allowed (98 resolved cases), compared with 51.3% across Art Unit 1623 over the last five years.
This examiner's interview lift is +71.3 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Jaret James Crews took 1,228 days on average from filing to allowance.
Jaret James Crews examines applications in Art Unit 1623 in Tech Center 1600 (Biotechnology & Pharmaceuticals).
